1. Home
  2. HPK vs ANNX Comparison

HPK vs ANNX Comparison

Compare HPK & ANNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo HighPeak Energy Inc.

HPK

HighPeak Energy Inc.

HOLD

Current Price

$6.70

Market Cap

907.3M

Sector

Energy

ML Signal

HOLD

Logo Annexon Inc.

ANNX

Annexon Inc.

HOLD

Current Price

$5.46

Market Cap

812.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HPK
ANNX
Founded
2019
2011
Country
United States
United States
Employees
50
N/A
Industry
Oil & Gas Production
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
907.3M
812.7M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
HPK
ANNX
Price
$6.70
$5.46
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
6
Target Price
$12.00
$16.50
AVG Volume (30 Days)
697.3K
3.7M
Earning Date
05-06-2026
05-11-2026
Dividend Yield
2.30%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$16,320.74
P/E Ratio
$13.73
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.85
$1.85
52 Week High
$10.41
$7.18

Technical Indicators

Market Signals
Indicator
HPK
ANNX
Relative Strength Index (RSI) 43.64 54.41
Support Level $6.55 $4.75
Resistance Level $7.26 $5.79
Average True Range (ATR) 0.47 0.37
MACD -0.12 0.09
Stochastic Oscillator 15.66 63.29

Price Performance

Historical Comparison
HPK
ANNX

About HPK HighPeak Energy Inc.

HighPeak Energy Inc is an independent crude oil and natural gas exploration and production company that explores for, develops and produces crude oil, NGL, and natural gas prominently in Howard County of the Midland Basin. The company operates in a single segment, which is crude oil and natural gas development, exploration, and production in the U.S. The majority of the company's revenue is derived from the Crude oil sales.

About ANNX Annexon Inc.

Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502, for Oral small molecule; and ANX009, for systemic autoimmune diseases.

Share on Social Networks: